ImmuPharma Surges 20% on P140 Licensing Progress

Edgen Stock

·Mar 27 2026, 10:58

Share to

Share to

Copy link

Key Takeaways

ImmuPharma PLC's stock gained significantly after the drug development company announced it is progressing toward a licensing deal for its core P140 autoimmune technology. The market's positive reaction is supported by recent milestones that strengthen the asset's scientific and intellectual property foundation, increasing the probability of a value-enhancing partnership in 2026.

ImmuPharma shares climbed 20% to 5.48p following news of advanced partnering discussions for its P140 platform.
The company bolstered its negotiating position with a positive initial patent report from the UK Intellectual Property Office.
Management is targeting a licensing deal in 2026 after holding a number of meetings at the Bio-Europe Spring healthcare conference.

ImmuPharma Stock Jumps 20% as Partnering Talks Advance

Shares in ImmuPharma PLC (AIM:IMM) increased 20% to 5.48p on March 27, 2026, after the company announced it is in advanced discussions with multiple potential partners for its P140 autoimmune technology. The announcement confirms that talks are progressing under signed confidentiality agreements. Company management attended the Bio-Europe Spring healthcare conference in Lisbon to further these negotiations, with the stated goal of securing a value-enhancing licensing deal within 2026. A successful agreement would provide significant non-dilutive funding and key validation for the P140 platform.

New Patent and Study Data Strengthen P140 Program

The market's confidence is underpinned by recent developments that de-risk the P140 asset. ImmuPharma received a supportive first Combined Search and Examination Report (CSER) from the UK Intellectual Property Office for its patent application filed last September. The company intends to leverage this positive step to file for broader protection across key commercial territories through a Patent Cooperation Treaty application. In parallel, a newly completed study successfully stress-tested the diagnostic test associated with P140, bolstering the statistical significance of its supporting data. These milestones provide a stronger scientific and intellectual property foundation, enhancing the platform's appeal to potential licensing partners.